Drug Trial Radar · NCT01125748
A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy
Last checked: Nov 20, 2026Latest source record: Oct 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
176
Actual
Start
May 2010
Primary completion
Aug 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 18, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 17 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a randomized, double-blind, placebo-controlled, 2-arm, 1-year study of participants who completed the EXCELS study (NCT00252135) and had received long-term treatment with Xolair. In addition, participants who did not participate in the EXCELS study but received long-term (\~5 years) treatment with Xolair were allowed to enter the study.
Conditions
- Allergic Asthma
Interventions
OmalizumabDrug
Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
PlaceboDrug
Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
Asthma therapiesDrug
Participants could receive 1 or more of the following medications as concomitant asthma therapy: Inhaled corticosteroids; long acting beta-agonists; zafirlukast or other leukotriene receptor antagonist; zileuton or other 5-lipoxygenase enzyme inhibitors; oral, inhaled, and/or nasal anticholinergic therapy; mast-cell stabilizers; theophyllines; chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Not Experiencing a Protocol-defined Severe Exacerbation During the StudyTime frame: Baseline to the end of the study (up to 52 weeks)
Locations
100 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Huntsville, Alabama
Site not named
Little Rock, Arkansas
Site not named
Bakersfield, California
Site not named
Fresno, California
Site not named
Fresno, California
Site not named
Granada Hills, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Napa, California
Site not named
Redwood City, California
Site not named
Sacramento, California
Site not named
San Francisco, California
Site not named
San Mateo, California
Site not named
Studio City, California
Site not named
Walnut Creek, California
Site not named
Centennial, Colorado
Site not named
Thornton, Colorado
Site not named
Waterbury, Connecticut
Site not named
Bay Pines, Florida
Site not named
Clearwater, Florida
Site not named
Loxahatchee Groves, Florida
Site not named
Ocala, Florida
Site not named
Pensacola, Florida
Site not named
Tampa, Florida
Site not named
West Palm Beach, Florida
Site not named
Albany, Georgia
Site not named
Columbus, Georgia
Site not named
Gainesville, Georgia
Site not named
Chicago, Illinois
Site not named
Glen Carbon, Illinois
Site not named
Park Ridge, Illinois
Site not named
Fort Wayne, Indiana
Site not named
Fort Wayne, Indiana
Site not named
Overland Park, Kansas
Site not named
Topeka, Kansas
Site not named
Lexington, Kentucky
Site not named
Mandeville, Louisiana
Site not named
Metairie, Louisiana
Site not named
Baltimore, Maryland
Site not named
Ellicott City, Maryland
Showing 40 of 100 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.